@article {Adis International Limited:2005:1176-3469:11,
	author = "Adis International Limited,",
	title = "Chronic Leukemias Progress and Challenges",
	journal = "Pharmaceutical & Diagnostic Innovation",
	volume = "3",
	year = "2005",
	abstract = "In the past decade, major progress has been made in treatment of the two major forms of chronic leukemia, myelogenous (CML) and lymphocytic (CLL) disease. Whereas the molecularly targeted agent Gleevec<SUP>&#174;</SUP> (imatinib mesylate) has revolutionized CML therapy, the development of the chemotherapeutic Fludara<SUP>&#174;</SUP> (fludarabine) and the targeted monoclonal antibody Campath<SUP>&#174;</SUP> (alemtuzumab) has offered significant benefit in CLL. However, challenges remain in both areas. Tumor cell resistance to Gleevec is becoming a significant problem in clinical therapy of CML, which is mainly being addressed by the development of novel compounds with the same mechanism of action as Gleevec but broader activity. As a consequence of the heterogenous nature of CLL, there is an unmet need for diagnostic markers with improved predictive capability to identify patients at high risk of disease progression, including those who would benefit from the currently available therapies.",
	pages = "11-13(3)",
	url = "http://www.ingentaconnect.com/content/adis/inn/2005/00000003/00000012/art00004"
}